Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
Is This Ultra-High Yield Dividend Stock a Steal at a 19% Discount?
09:56am, Monday, 11'th Aug 2025
Key Points in This Article: Pfizer's (PFE) stock has fallen 19% from its 52-week high and 50% over three years due to declining COVID-19 product sales and patent cliff concerns.
2 Beaten-Down Stocks to Buy and Hold
09:15am, Sunday, 10'th Aug 2025
The 2025 stock market has been highly volatile, to say the least. While many top stocks have risen above the fray during periods of market recovery, others haven't followed that upward trend.
Meet the 7.3% Yield Dividend Stock That Could Soar in 2026
06:05am, Sunday, 10'th Aug 2025
It's been a tough stretch for pharmaceutical giant Pfizer (PFE 1.42%). The company enjoyed a vaccine windfall during the COVID-19 pandemic, but revenue and profits cratered as the pandemic eased and t
5 Strong Buy Dividend Stocks for Huge Passive Income
08:14am, Saturday, 09'th Aug 2025
A value stock is generally a company that trades at a price lower than its fundamental value or what its performance suggests it should be worth.
4 High-Yield Blue Chips Near 52-Week Lows: All Are Strong Buys Now
09:17am, Friday, 08'th Aug 2025
Blue-chip stocks are shares of large, well-established, financially stable companies with a history of consistent and reliable performance.
CureVac settles patent dispute litigation with Pfizer and BioNTech
09:00pm, Thursday, 07'th Aug 2025
CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.
Pfizer's Turnaround Has Truly Started (Earnings Update)
06:20am, Thursday, 07'th Aug 2025
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting, signaling a successful turnaround is underway. Key drugs like Vyndaqel, Paxlovid, and Lobr
This 7% Yielding Stock Just Raised Its Profit Forecast. Is It Time to Buy?
05:57am, Thursday, 07'th Aug 2025
Incoming patent cliffs regarding some of Pfizer's (PFE -3.25%) largest revenue streams have been pressuring the pharmaceutical stock. The price is down, but its dividend payout keeps rising.
Pfizer Q2: Dividends Speak Louder Than EPS
05:42pm, Wednesday, 06'th Aug 2025
At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. However, given the strong EPS headwinds and large EPS uncertainties, I suggest investors focus on other profit
1 Reason to Buy Pfizer (PFE) Stock
07:15am, Wednesday, 06'th Aug 2025
I can actually think of multiple reasons to buy shares of Pfizer (PFE 4.82%) stock, but if I had to focus on only one, I'd choose its dividend. The stock's dividend yield was recently a whopping 7.4%!
Final Trade: PFE, SNV, PLTR & VLO
06:18pm, Tuesday, 05'th Aug 2025
The final trades of the day with CNBC's Mike Santoli and the “Fast Money” traders.
Pfizer CEO talks lowering drug prices, tariffs, and earnings
04:48pm, Tuesday, 05'th Aug 2025
Pfizer (PFE) topped second quarter expectations, but looming Trump-era pharmaceutical tariffs remain a concern. Pfizer CEO Albert Bourla joins Market Domination to discuss the company's earnings resul
Pfizer Inc. (PFE) Q2 2025 Earnings Call Transcript
04:46pm, Tuesday, 05'th Aug 2025
Pfizer Inc. (NYSE:PFE ) Q2 2025 Earnings Conference Call August 5, 2025 10:00 AM ET Company Participants Aamir Malik - Corporate Participant Albert Bourla - Chairman of the Board & CEO Alexandre de Ge
Why Shares of Pfizer Soared Today
04:23pm, Tuesday, 05'th Aug 2025
Shares of the large pharmaceutical company Pfizer (PFE 5.18%) closed up over 5% today after a strong earnings report that included raising its full-year profit outlook for 2025.
Pfizer Q2 Earnings Review: Upside At Last As CEO Prepares For Trump Policy Battle
03:41pm, Tuesday, 05'th Aug 2025
Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth i
